Future of high-density lipoprotein infusion therapies: Potential for clinical management of vascular disease

Circulation

Volumn 128, Issue 10, 2013, Pages 1112-1121

  Kingwell, Bronwyn A ^a   Chapman, M John ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; RECOMBINANT LECITHIN CHOLESTEROL ACYLTRANSFERASE; ROSUVASTATIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; ATHERECTOMY; ATHEROMA; ATHEROSCLEROSIS; DRUG INFUSION; FAMILIAL HYPOALPHALIPOPROTEINEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INTRACELLULAR SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; UPREGULATION; VASCULAR DISEASE;

ACUTE CORONARY SYNDROME; APOLIPOPROTEINS; ATHEROSCLEROSIS; CEREBROVASCULAR DISORDERS; LIPOPROTEINS, HDL; PERIPHERAL ARTERIAL DISEASE; THERAPY;

DISEASE MANAGEMENT; FORECASTING; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPROTEINS, HDL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR DISEASES;

EID: 84883619573     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.002683     Document Type: Article

References (73)

1. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-1310.
2. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
3. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099.
4. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
5. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-1291.
6. Heinecke JW. The not-so-simple HDL story: a new era for quantifying HDL and cardiovascular risk? Nat Med. 2012;18:1346-1347.
7. Rader DJ, Tall AR. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344-1346.
8. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010;21:312-318.
9. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2013;34:719-728.
10. Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation. 2012;125:1147-1156.
11. Davies MJ. Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995. Circulation. 1996;94:2013-2020.
12. Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, Schiele F, Dudek D, Fahy M, Xu K, Lansky A, Templin B, Zhang Z, de Bruyne B, Serruys PW, Stone GW. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging. 2012;5(suppl):S42-S52.
13. de Souza JA, Vindis C, Nègre-Salvayre A, Rye KA, Couturier M, Therond P, Chantepie S, Salvayre R, Chapman MJ, Kontush A. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein AI. J Cell Mol Med. 2010;14:608-620.
14. Kontush A, Therond P, Zerrad A, Couturier M, Négre-Salvayre A, de Souza JA, Chantepie S, Chapman MJ. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol. 2007;27:1843-1849.
15. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ, Rye KA, Chin-Dusting J, Hoang A, Sviridov D, Celermajer DS, Kingwell BA. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol. 2009;53:962-971.
16. Zerrad-Saadi A, Therond P, Chantepie S, Couturier M, Rye KA, Chapman MJ, Kontush A. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein AI and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol. 2009;29:2169-2175.
17. Kontush A, Chapman MJ. High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics. Hoboken, NHJ: John Wiley and Sons; 2012.
18. Calkin AC, Drew BG, Ono A, Duffy SJ, Gordon MV, Schoenwaelder SM, Sviridov D, Cooper ME, Kingwell BA, Jackson SP. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation. 2009;120:2095-2104.
19. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low highdensity lipoprotein. Circulation. 2003;107:2944-2948.
20. Nieuwdorp M, Vergeer M, Bisoendial RJ, op 't Roodt J, Levels H, Birjmohun RS, Kuivenhoven JA, Basser R, Rabelink TJ, Kastelein JJ, Stroes ES. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia. 2008;51:1081-1084.
21. Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Lüscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
22. Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011;124:555-562.
23. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Courten B, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119:2103-2111.
24. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol. 2012;8:237-245.
25. Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010;30:1642-1648.
26. Barter P, Boden W, Nicholls S. AIM-HIGH fallout: experts disagree over niacin's niche. 2011. http://www.Theheart.Org/article/1312479.do. Accessed August 14, 2013.
27. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-164.
28. Bishop BM. Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process? Am J Ther. April 5, 2013. DOI: 10.1097/MJT.0b013e31828b8463. http://journals.lww.com/americantherapeutics/pages/default.aspxv. Accessed August 14, 2013.
29. Larach DB, deGoma EM, Rader DJ. Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr Cardiol Rep. 2012;14:684-691.
30. Vucic E, Rosenson RS. Recombinant high-density lipoprotein formulations. Curr Atheroscler Rep. 2011;13:81-87.
31. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol. 1999;19:979-989.
32. Gille A, Easton R, Wright S, Shear C. CSL112, a novel formulation of human apolipoprotein AI, dramatically increases cholesterol efflux capacity in healthy subjects: a placebo-controlled, double-blinded, randomized single ascending dose study [abstract]. Circulation. 2012;126:A11855.
33. Keyserling CH, Hunt TL, Klepp HM, Dcott RA, Barbaras R, Schwendeman A, Lalwani N, Dasseux J-L. CER-001, a synthetic HDLmimetic, safely mobilizes cholesterol in healthy dyslipidemic volunteers [abstract]. Circulation. 2011;124:A15525.
34. Kee P, Rye KA, Taylor JL, Barrett PH, Barter PJ. Metabolism of apoAI as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits. Arterioscler Thromb Vasc Biol. 2002;22:1912-1917.
35. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particlespecific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol. 2009;29:870-876.
36. Huang R, Silva RA, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, Hodges TJ, Davidson WS. Apolipoprotein AI structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol. 2011;18:416-422.
37. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675-1682.
38. Easton R, Tremper L, Shear C. Safety and pharmakokinetics of a novel formulation of human apolipoprotein AI (CSL112) in healthy subjects: Results of a placebo-controlled, randomized multiple ascending dose study. Circulation. 2012;126:A11892.
39. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayikçioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006;295:2046-2056.
40. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
41. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, Nissen SE. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein AI Milano. J Am Coll Cardiol. 2006;47:992-997.
42. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoAI Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
43. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078-2087.
44. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Maltais JA, Weissman NJ, Fitzgerald PJ, Brewer HB Jr. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55:2727-2735.
45. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
46. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508.
47. Hattori K, Ozaki Y, Ismail TF, Okumura M, Naruse H, Kan S, Ishikawa M, Kawai T, Ohta M, Kawai H, Hashimoto T, Takagi Y, Ishii J, Serruys PW, Narula J. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging. 2012;5:169-177.
48. Califf RM. Biomarkers, putative surrogates, surrogates, and decision making. Circ Cardiovasc Imaging. 2013;6:6-7.
49. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, Woollard K, Lyon S, Sviridov D, Dart AM. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008;103:1084-1091.
50. van Oostrom O, Nieuwdorp M, Westerweel PE, Hoefer IE, Basser R, Stroes ES, Verhaar MC. Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2007;27:1864-1865.
51. Carvalho LS, Cintra RM, Moura FA, Martins NV, Quinaglia E Silva JC, Coelho OR, Sposito AC; Brasilia Heart Study Group. High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction. Atherosclerosis. 2012;220:231-236.
52. Drew BG, Carey AL, Natoli AK, Formosa MF, Vizi D, Reddy-Luthmoodoo M, Weir JM, Barlow CK, van Hall G, Meikle PJ, Duffy SJ, Kingwell BA. Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus. J Lipid Res. 2011;52:572-581.
53. Hoang A, Drew BG, Low H, Remaley AT, Nestel P, Kingwell BA, Sviridov D. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J. 2012;33:657-665.
54. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE. Intravenous apoAI/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586-1593.
55. Clinicaltrials.Gov. Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients-Efficacy and Safety: the CHI SQUARE Trial. http://clinicaltrials.Gov/ct2/show/nct01201837. Accessed August 14, 2013.
56. Clinicaltrials.Gov. Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE) http://clinicaltrials. Gov/ct2/show/results/nct01412034. Accessed August 14, 2013.
57. Sankaranarayanan S, de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Weibel GL, Rothblat GH. Importance of macrophage cholesterol content on the flux of cholesterol mass. J Lipid Res. 2010;51:3243-3249.
58. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, Rayner K, Moore K, Garabedian M, Fisher EA. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocytederived cells. Proc Natl Acad Sci USA. 2011;108:7166-7171.
59. Cimmino G, Ibanez B, Vilahur G, Speidl WS, Fuster V, Badimon L, Badimon JJ. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoAI(Milano). J Cell Mol Med. 2009;13:3226-3235.
60. Goffinet M, Tardy C, Bluteau A, Boubekeur N, Baron R, Keyserling CH, Barbaras R, Lalwani N, Dasseux J-L. Anti-atherosclerotic effect of CER-001, an engineered HDL-mimetic, in the high-fat diet-fed LDLr knock-out mouse [abstract]. Circulation. 2012;126:A18667.
61. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905-1919.
62. Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim MJ, Van Eck M, Couvert P, Carrie A, Giral P, Chapman MJ, Guerin M, Le Goff W. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol. 2009;29:1930-1936.
63. Ji Y, Jian B, Wang N, Sun Y, Moya ML, Phillips MC, Rothblat GH, Swaney JB, Tall AR. Scavenger receptor BI promotes high density lipoproteinmediated cellular cholesterol efflux. J Biol Chem. 1997;272:20982-20985.
64. Soumian S, Gibbs R, Davies A, Albrecht C. mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease. J Clin Pathol. 2005;58:1255-1260.
65. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoEdeficient mice. Proc Natl Acad Sci USA. 2006;103:3781-3786.
66. Gille A, Diditchenko S, Leary E, Shear C, Rader D, Wright S. CSL112, a novel formulation of human apoAI, enhances the capacity of serum to efflux cholesterol from macrophages [abstract]. Arterioscler Thromb Vasc Biol. 2012;32:A502.
67. Easton R, Diditchenko S, Spycher M, Edler M, Bolli R, Bossart O, Stadler D, Pragst I, Haynes J, Wright S. CSL112, a novel formulation of human apoAI rapidly activates lecithin-cholesterol acyltransferase upon infusion into rabbits and monkeys. J Am Coll Cardiol. 2012;59:E492 [Abstract].
68. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
69. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340-347.
70. de la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, Tabita-Martinez J, Wolfe ML, Badellino K, Pruscino L, Mehta NN, Asztalos BF, Reilly MP. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis. 2012;222:390-394.
71. Cornel JH, Becker RC, Goodman SG, Husted S, Katus H, Santoso A, Steg G, Storey RF, Vintila M, Sun JL, Horrow J, Wallentin L, Harrington R, James S. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2012;164:334-342
72. Golledge J, Wolanski P, Parr A, Buttner P. Measurement and determinants of infrarenal aortic thrombus volume. Eur Radiol. 2008;18:1987-1994.
73. Torsney E, Pirianov G, Charolidi N, Shoreim A, Gaze D, Petrova S, Laing K, Meisinger T, Xiong W, Baxter BT, Cockerill GW. Elevation of plasma high-density lipoproteins inhibits development of experimental abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2012;32:2678-2686.